News

The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has, by consensus, adopted a positive opinion recommending marketing authorisation for…
Read More...

CytoDyn Inc. announced that new data shows that a weekly dose of 525 mg and 700 mg of leronlimab yielded approximately a 90% response rate for those HIV-infected patients who pass the…
Read More...

Purdue Pharma L.P. announced that it has entered into a landmark agreement with the state of Oklahoma that will establish a National Center for Addiction Studies and Treatment at…
Read More...

AbbVie announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque…
Read More...

RegeneRx Biopharmaceuticals, a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited, a Hong…
Read More...

Eli Lilly and Company and ImmuNext announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines…
Read More...

The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does…
Read More...

Aimmune Therapeutics announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral…
Read More...

MilliporeSigma officially opened its new M Lab Collaboration Center in Molsheim, France. The center is MilliporeSigma's first in Europe and ninth worldwide, providing biopharmaceutical…
Read More...

GlaxoSmithKline plc announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell…
Read More...

PARIS & Vivet Therapeutics and Pfizer announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and…
Read More...

Conatus Pharmaceuticals Inc. announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and…
Read More...

Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex conditions through a new exclusive distribution agreement. After making…
Read More...

Merck announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector…
Read More...

Petra Pharma Corporation announced that it has secured a global license from Takeda Pharmaceutical Company Limited to develop, manufacture and commercialize serabelisib and two…
Read More...

HemoShear Therapeutics, LLC announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial…
Read More...

Merck and NGM Biopharmaceuticals announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year…
Read More...

Alexion Pharmaceuticals and Affibody AB announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development,…
Read More...

The Mundipharma network of independent associated companies is pleased to launch the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin,…
Read More...